Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
Precigen (PGEN), a biopharmaceutical company focused on gene and cell therapies, has scheduled the release of its full year 2024 financial results for March 19, 2025. The company will host a conference call at 4:30 PM ET to discuss the results and provide business updates.
Investors can access the conference call by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants should dial in 10-15 minutes before the scheduled call time. Additional event details are available on Precigen's website under the Events & Presentations section.
Precigen specializes in developing next-generation gene and cell therapies targeting immuno-oncology, autoimmune disorders, and infectious diseases using precision technology. The company focuses on creating affordable biotherapeutics through controlled innovation.
Precigen (PGEN), un'azienda biofarmaceutica specializzata in terapie geniche e cellulari, ha programmato il rilascio dei suoi risultati finanziari per l'intero anno 2024 per il 19 marzo 2025. L'azienda ospiterà una conferenza telefonica alle 16:30 ET per discutere i risultati e fornire aggiornamenti aziendali.
Gli investitori possono accedere alla conferenza telefonica componendo il numero 1-800-836-8184 (Nord America) o 1-646-357-8785 (Internazionale). I partecipanti sono invitati a chiamare 10-15 minuti prima dell'orario programmato. Ulteriori dettagli sull'evento sono disponibili sul sito web di Precigen nella sezione Eventi e Presentazioni.
Precigen si specializza nello sviluppo di terapie geniche e cellulari di nuova generazione mirate all'immuno-oncologia, ai disturbi autoimmuni e alle malattie infettive utilizzando tecnologie di precisione. L'azienda si concentra sulla creazione di bioterapici accessibili attraverso un'innovazione controllata.
Precigen (PGEN), una empresa biofarmacéutica centrada en terapias génicas y celulares, ha programado la publicación de sus resultados financieros para el año completo 2024 para el 19 de marzo de 2025. La empresa llevará a cabo una llamada de conferencia a las 4:30 PM ET para discutir los resultados y proporcionar actualizaciones sobre el negocio.
Los inversores pueden acceder a la llamada de conferencia marcando el 1-800-836-8184 (América del Norte) o el 1-646-357-8785 (Internacional). Se recomienda a los participantes que llamen de 10 a 15 minutos antes de la hora programada. Detalles adicionales sobre el evento están disponibles en el sitio web de Precigen en la sección de Eventos y Presentaciones.
Precigen se especializa en el desarrollo de terapias génicas y celulares de próxima generación dirigidas a la inmuno-oncología, trastornos autoinmunes y enfermedades infecciosas utilizando tecnología de precisión. La empresa se centra en crear biofármacos asequibles a través de una innovación controlada.
프레시겐 (PGEN), 유전자 및 세포 치료에 중점을 둔 생명공학 회사는 2024 회계연도 전체 재무 결과를 2025년 3월 19일에 발표할 예정입니다. 이 회사는 오후 4:30 ET에 결과를 논의하고 사업 업데이트를 제공하기 위한 컨퍼런스 콜을 개최할 것입니다.
투자자들은 1-800-836-8184 (북미) 또는 1-646-357-8785 (국제)로 전화하여 컨퍼런스 콜에 접속할 수 있습니다. 참가자들은 예정된 전화 시간 10-15분 전에 전화하는 것이 좋습니다. 이벤트에 대한 추가 세부 정보는 프레시겐 웹사이트의 이벤트 및 발표 섹션에서 확인할 수 있습니다.
프레시겐은 정밀 기술을 사용하여 면역 종양학, 자가면역 질환 및 감염병을 목표로 하는 차세대 유전자 및 세포 치료제를 개발하는 데 전문화되어 있습니다. 이 회사는 통제된 혁신을 통해 저렴한 생물 치료제를 만드는 데 중점을 두고 있습니다.
Precigen (PGEN), une entreprise biopharmaceutique spécialisée dans les thérapies géniques et cellulaires, a prévu la publication de ses résultats financiers pour l'année complète 2024 pour le 19 mars 2025. L'entreprise organisera une conférence téléphonique à 16h30 ET pour discuter des résultats et fournir des mises à jour sur les activités.
Les investisseurs peuvent accéder à la conférence téléphonique en composant le 1-800-836-8184 (Amérique du Nord) ou le 1-646-357-8785 (International). Les participants sont invités à se connecter 10 à 15 minutes avant l'heure prévue de l'appel. Des détails supplémentaires sur l'événement sont disponibles sur le site Web de Precigen dans la section Événements et Présentations.
Precigen est spécialisée dans le développement de thérapies géniques et cellulaires de nouvelle génération ciblant l'immuno-oncologie, les troubles auto-immuns et les maladies infectieuses à l'aide de technologies de précision. L'entreprise se concentre sur la création de biothérapeutiques abordables grâce à une innovation contrôlée.
Precigen (PGEN), ein biopharmazeutisches Unternehmen, das sich auf Gen- und Zelltherapien spezialisiert hat, hat die Veröffentlichung seiner Finanzergebnisse für das Gesamtjahr 2024 für den 19. März 2025 geplant. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und Unternehmensupdates zu geben.
Investoren können auf die Telefonkonferenz zugreifen, indem sie 1-800-836-8184 (Nordamerika) oder 1-646-357-8785 (International) wählen. Teilnehmer sollten 10-15 Minuten vor der geplanten Zeit anrufen. Weitere Einzelheiten zur Veranstaltung sind auf der Website von Precigen im Abschnitt Veranstaltungen & Präsentationen verfügbar.
Precigen ist auf die Entwicklung von Therapien der nächsten Generation spezialisiert, die sich auf Immunonkologie, Autoimmunerkrankungen und Infektionskrankheiten konzentrieren, wobei Präzisionstechnologie eingesetzt wird. Das Unternehmen legt Wert auf die Schaffung erschwinglicher biotherapeutischer Produkte durch kontrollierte Innovation.
- None.
- None.
The conference call may be accessed by dialing 1-800-836-8184 (
Event details can be found on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with Precision®
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.
Cautionary Statement Regarding Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Investor Contact:
Steven M. Harasym
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M. Gregory
press@precigen.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-announce-full-year-2024-financial-results-and-provide-business-updates-on-march-19th-302400648.html
SOURCE Precigen, Inc.
FAQ
When will Precigen (PGEN) release its full year 2024 financial results?
What time is Precigen's (PGEN) earnings conference call scheduled for March 19, 2025?
What are the dial-in numbers for Precigen's (PGEN) 2024 earnings call?
What are Precigen's (PGEN) main therapeutic focus areas?
